Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
EBS

EBS - Emergent BioSolutions Inc Stock Price, Fair Value and News

6.04USD-0.28 (-4.43%)Market Closed

Market Summary

EBS
USD6.04-0.28
Market Closed
-4.43%

EBS Stock Price

View Fullscreen

EBS RSI Chart

EBS Valuation

Market Cap

316.5M

Price/Earnings (Trailing)

-0.56

Price/Sales (Trailing)

0.27

EV/EBITDA

-1.98

Price/Free Cashflow

-2.39

EBS Price/Sales (Trailing)

EBS Profitability

EBT Margin

-47.11%

Return on Equity

-85.15%

Return on Assets

-31.34%

Free Cashflow Yield

-41.77%

EBS Fundamentals

EBS Revenue

Revenue (TTM)

1.2B

Rev. Growth (Yr)

82.84%

Rev. Growth (Qtr)

8.6%

EBS Earnings

Earnings (TTM)

-565.3M

Earnings Growth (Yr)

104.83%

Earnings Growth (Qtr)

118.18%

Breaking Down EBS Revenue

Last 7 days

-5.2%

Last 30 days

17.9%

Last 90 days

168.9%

Trailing 12 Months

-21.9%

How does EBS drawdown profile look like?

EBS Financial Health

Current Ratio

1.08

Debt/Equity

0.67

Debt/Cashflow

-0.19

EBS Investor Care

Shares Dilution (1Y)

3.87%

Diluted EPS (TTM)

-10.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20241.2B000
2023977.0M1.1B1.1B1.0B
20221.7B1.6B1.5B1.1B
20211.7B1.7B1.6B1.8B
20201.1B1.3B1.3B1.6B
2019855.2M878.2M1.0B1.1B
2018561.8M681.2M705.5M782.4M
2017502.7M512.3M518.8M560.9M
2016540.1M512.4M496.9M488.8M
2015448.4M457.1M477.5M489.3M
2014323.5M351.4M400.3M450.1M
2013274.7M286.7M309.2M312.7M
2012305.2M287.4M295.2M281.9M
2011257.9M283.9M268.7M273.4M
20100251.9M269.0M286.2M
2009000234.8M

Tracking the Latest Insider Buys and Sells of Emergent BioSolutions Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 08, 2024
lindahl richard s
sold (taxes)
-16,917
6.19
-2,733
evp, chief financial officer
Jun 08, 2024
hartzel william
sold (taxes)
-7,223
6.19
-1,167
svp, bioservices
Jun 08, 2024
fox jennifer lynne
sold (taxes)
-14,707
6.19
-2,376
evp, ext aff, gc, corp sec
Jun 08, 2024
williams paul anthony
sold (taxes)
-2,872
6.19
-464
svp, products business
Jun 08, 2024
glessner coleen
sold (taxes)
-7,731
6.19
-1,249
evp, quality & ethics, and cpl
Jun 04, 2024
zoon kathryn c
sold
-61,100
6.11
-10,000
-
May 29, 2024
zoon kathryn c
sold
-8,436
4.61
-1,830
-
May 23, 2024
richard ronald
acquired
-
-
17,430
-
May 23, 2024
sullivan louis w
acquired
-
-
17,430
-
May 23, 2024
katkin keith
acquired
-
-
17,430
-

1–10 of 50

Which funds bought or sold EBS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
sold off
-100
-504
-
-%
May 28, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
2,000
34,000
-%
May 24, 2024
Cetera Investment Advisers
new
-
432,506
432,506
-%
May 20, 2024
Virtu Financial LLC
sold off
-100
-71,000
-
-%
May 20, 2024
EMC Capital Management
sold off
-100
-10,000
-
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-50.13
-281,206
311,635
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-38.93
-7,317
13,227
-%
May 16, 2024
Tidal Investments LLC
new
-
33,781
33,781
-%
May 15, 2024
Avidity Partners Management LP
new
-
4,827,240
4,827,240
0.16%
May 15, 2024
Royal Bank of Canada
reduced
-95.16
-57,000
3,000
-%

1–10 of 46

Are Funds Buying or Selling EBS?

Are funds buying EBS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EBS
No. of Funds

Unveiling Emergent BioSolutions Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jun 07, 2024
blackrock inc.
12.7%
6,638,414
SC 13G/A
Feb 13, 2024
vanguard group inc
5.73%
2,974,638
SC 13G/A
Feb 09, 2024
charles schwab investment management inc
5.54%
2,873,984
SC 13G
Jan 23, 2024
state street corp
2.05%
1,062,951
SC 13G/A
Jan 19, 2024
blackrock inc.
18.1%
9,399,197
SC 13G/A
Jan 18, 2024
millennium management llc
4.0%
2,095,662
SC 13G/A
Nov 07, 2023
blackrock inc.
18.1%
9,381,892
SC 13G/A
Oct 10, 2023
state street corp
2.18%
1,131,955
SC 13G/A
Oct 10, 2023
vanguard group inc
5.11%
2,646,366
SC 13G/A
Sep 07, 2023
blackrock inc.
12.4%
6,400,203
SC 13G/A

Recent SEC filings of Emergent BioSolutions Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 07, 2024
SC 13G/A
Major Ownership Report
Jun 06, 2024
4
Insider Trading
Jun 04, 2024
144
Notice of Insider Sale Intent
May 31, 2024
4
Insider Trading
May 29, 2024
8-K
Current Report

Peers (Alternatives to Emergent BioSolutions Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
350.0B
85.6B
-3.84% -9.54%
9.1
4.09
5.68% 202.39%
327.6B
61.4B
0.70% 19.17%
142.08
5.34
6.11% -82.30%
160.0B
29.5B
-2.39% 35.63%
42.52
5.42
12.76% -52.47%
156.6B
35.0B
-2.74% -31.33%
134.79
4.47
-26.40% -92.03%
79.1B
27.4B
-4.74% -17.19%
163.34
2.88
1.51% -91.32%
19.5B
16.0B
2.01% 128.69%
-39.52
1.22
7.23% 71.10%
MID-CAP
4.2B
1.7B
0.53% -21.09%
9.66
2.43
54.01% 364.56%
3.8B
4.6B
-9.64% -15.95%
-492.88
0.83
-0.06% 94.55%
2.3B
9.0B
-11.50% -15.30%
-4.98
0.25
10.01% -27.45%
2.0B
676.2M
-4.53% -14.12%
12.84
2.94
30.38% 66.04%
SMALL-CAP
1.3B
743.2M
-11.06% 3.51%
-3.83
1.81
24.65% 80.36%
22.8M
1.3M
-1.44% -45.62%
-3.08
17.54
-98.14% -104.71%
16.7M
89.6M
-3.92% -20.33%
-1.17
0.19
287.27% -129.41%
2.5M
21.5M
-5.26% -89.97%
-0.32
0.11
66.16% 61.84%
347.8K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Emergent BioSolutions Inc News

Latest updates
Yahoo New Zealand News41 hours ago
InvestorPlace02 May 202407:00 am

Emergent BioSolutions Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue8.6%300277271338164330240243305733286377377583385395193360312243191
Operating Expenses-18.7%261320513631312386285315301438364383248342324269204283241250218
  S&GA Expenses-5.6%85.0090.0086.0091.0010193.0082.0081.0085.0095.0082.0091.0081.0083.0076.0076.0070.0072.0065.0071.0065.00
  R&D Expenses-48.6%15.0029.0015.0026.0041.0048.0042.0050.0046.0038.0050.0049.0053.0063.0084.0048.0043.0063.0053.0064.0046.00
EBITDA Margin40.9%-0.29*-0.49*-0.48*-0.32*-0.18*-0.03*0.18*0.19*0.22*0.26*0.28*0.32*---------
Interest Expenses12.0%24.0022.0020.0029.0018.0013.009.008.008.009.008.009.009.009.008.006.009.009.0010.0010.0010.00
Income Taxes162.6%3.00-4.95-2.5011.0026.002.0020.00-26.40-0.1078.00-12.803.0016.0071.0016.0028.00-8.8025.0016.00-5.60-11.80
Earnings Before Taxes122.2%12.00-54.50-265-250-160-63.30-67.20-82.80-3.80256-45.507.0085.0025855.00121-21.3071.0059.00-15.10-37.80
EBT Margin32.4%-0.47*-0.70*-0.67*-0.51*-0.38*-0.19*0.07*0.08*0.13*0.17*0.19*0.24*---------
Net Income118.2%9.00-49.50-263-261-186-67.00-87.10-52.90-4.60193-40.40-0.5067.0018540.0093.00-12.5047.0043.00-9.50-26.10
Net Income Margin34.2%-0.48*-0.72*-0.71*-0.56*-0.40*-0.19*0.03*0.06*0.09*0.12*0.13*0.17*---------
Free Cashflow-454.6%-73.4021.0047.00-126-19969.00-101-47.70-69.50282-38.50-96.70---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.1%1,8041,8231,8932,1792,9503,1662,8962,7352,7802,9582,8682,9152,9002,8832,6162,4662,2792,3272,3342,3212,154
  Current Assets0.4%6826807217781,2211,2101,0981,0841,1001,2701,1121,1621,1811,196959796627686700693529
    Cash Equivalents-29.7%79.0011288.0089.00430643241358436576404448548622415269182168139178137
  Inventory1.4%333329354354368351528426401345365386407307270236248223230232211
  Net PPE-0.9%379383395396717818807798808800769744693644607580549542529521513
  Goodwill----218218218225225225225267267267267267266266267269268268
Liabilities-2.9%1,1401,1741,1961,2231,7471,7791,4631,2221,2051,3461,3451,3721,3771,4361,3651,2671,2041,2391,2991,3321,166
  Current Liabilities-3.2%6306516646931,2161,229264277249374365378370385299294207216275301248
  Long Term Debt0.0%4474474484484484491,032794802809817825833841849758763798813830732
    LT Debt, Current11.0%459414----------------10.0010.0010.00
    LT Debt, Non Current0.0%4474474484484484491,032794802809817825833841849758763798813830732
Shareholder's Equity2.2%6646496979581,2041,3881,4331,5081,5671,6121,5231,5441,5231,4511,2521,1991,0751,0911,035989987
  Retained Earnings41.3%-12.80-21.8028.00290551739806898954950769801797727542502409422375332341
  Additional Paid-In Capital0.6%910904900896878874860849835829817804790785771759726716709702690
Shares Outstanding0.4%52.0052.0052.0052.0050.0050.0050.0050.0051.0054.0054.0054.00---------
Float----381---1,500---3,400---4,200---2,500-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-295.0%-62.6032.0060.00-114-18493.00-74.00-15.60-37.3032817.00-29.705.0024610512858.00122-3.10-35.80105
  Share Based Compensation47.5%6.004.004.008.007.0012.0011.0012.0010.0010.0010.0011.0011.0011.0010.0024.007.006.006.008.007.00
Cashflow From Investing5.3%-10.80-11.40-18.90258-15.10-45.40-271-32.10-32.20-45.80-55.20-67.00-56.10-36.90-45.70-45.10-24.20-36.10-15.30-24.10-21.40
Cashflow From Financing766.0%41.005.00-43.00-486-10.50353229-30.70-70.50-110-5.00-3.80-22.20-2.3087.005.00-20.00-57.90-19.70100-58.40
  Buy Backs--------23.0052.00106-----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

EBS Income Statement

2024-03-31
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues [Abstract]  
Total revenues$ 300.4$ 164.3
Operating expenses:  
Cost of goods and services sold144.6152.9
Research and development15.140.7
Selling, general and administrative84.7101.3
Amortization of intangible assets16.217.0
Total operating expenses260.6311.9
Income (loss) from operations39.8(147.6)
Other income (expense):  
Interest expense(24.3)(17.9)
Other, net(3.4)4.9
Total other income (expense), net(27.7)(13.0)
Income (loss) before income taxes12.1(160.6)
Income tax provision3.125.6
Net income (loss)$ 9.0$ (186.2)
Earnings Per Share, Diluted [Abstract]  
Basic (in dollars per share)$ 0.17$ (3.71)
Diluted (in dollars per share)$ 0.17$ (3.71)
Weighted average shares outstanding  
Basic (in shares)52.250.2
Diluted (in shares)52.250.2
Total Product sales, net  
Revenues [Abstract]  
Product sales$ 273.9$ 143.4
Commercial Product sales  
Revenues [Abstract]  
Product sales118.5106.2
Operating expenses:  
Cost of goods and services sold52.145.8
MCM Product sales  
Revenues [Abstract]  
Product sales155.437.2
Operating expenses:  
Cost of goods and services sold62.255.4
Total Bioservices revenues  
Revenues [Abstract]  
Total Bioservices revenues18.514.4
Operating expenses:  
Cost of goods and services sold30.351.7
Services  
Revenues [Abstract]  
Product sales18.312.6
Leases  
Revenues [Abstract]  
Leases0.21.8
Contracts and grants  
Revenues [Abstract]  
Product sales$ 8.0$ 6.5

EBS Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 78.5$ 111.7
Restricted cash0.50.0
Accounts receivable, net233.5191.0
Inventories, net333.4328.9
Prepaid expenses and other current assets36.547.9
Total current assets682.4679.5
Property, plant and equipment, net379.4382.8
Intangible assets, net550.4566.6
Other assets191.4194.3
Total assets1,803.61,823.2
Current liabilities:  
Accounts payable100.2112.2
Accrued expenses14.318.6
Accrued compensation42.074.1
Debt, current portion459.2413.7
Other current liabilities14.532.7
Total current liabilities630.2651.3
Debt, net of current portion446.7446.5
Deferred tax liability34.847.2
Other liabilities28.028.9
Total liabilities1,139.71,173.9
Stockholders' equity:  
Preferred stock, $0.001 par value per share; 15.0 shares authorized, no shares issued or outstanding0.00.0
Common stock, $0.001 par value per share; 200.0 shares authorized, 58.0 and 57.8 shares issued; 52.4 and 52.2 shares outstanding, respectively0.10.1
Treasury stock, at cost, 5.6 and 5.6 common shares, respectively(227.7)(227.7)
Additional paid-in capital909.8904.4
Accumulated other comprehensive loss, net(5.5)(5.7)
Accumulated deficit(12.8)(21.8)
Total stockholders’ equity663.9649.3
Total liabilities and stockholders’ equity$ 1,803.6$ 1,823.2
EBS
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
 WEBSITEemergentbiosolutions.com
 INDUSTRYPharmaceuticals
 EMPLOYEES2500

Emergent BioSolutions Inc Frequently Asked Questions


What is the ticker symbol for Emergent BioSolutions Inc? What does EBS stand for in stocks?

EBS is the stock ticker symbol of Emergent BioSolutions Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Emergent BioSolutions Inc (EBS)?

As of Wed Jun 12 2024, market cap of Emergent BioSolutions Inc is 331.18 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EBS stock?

You can check EBS's fair value in chart for subscribers.

What is the fair value of EBS stock?

You can check EBS's fair value in chart for subscribers. The fair value of Emergent BioSolutions Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Emergent BioSolutions Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EBS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Emergent BioSolutions Inc a good stock to buy?

The fair value guage provides a quick view whether EBS is over valued or under valued. Whether Emergent BioSolutions Inc is cheap or expensive depends on the assumptions which impact Emergent BioSolutions Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EBS.

What is Emergent BioSolutions Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, EBS's PE ratio (Price to Earnings) is -0.59 and Price to Sales (PS) ratio is 0.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EBS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Emergent BioSolutions Inc's stock?

In the past 10 years, Emergent BioSolutions Inc has provided -0.119 (multiply by 100 for percentage) rate of return.